Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia is part of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Their mission is to finally make personalized medicine a reality and bring high caliber innovation from research bench to bedside as efficiently as possible to benefit patients now, rather than in ten years.
Official Representative: David Macdonald, Chief Executive Officer
Aviir was founded in 2005 by cardiologists and researchers from the Stanford School of Medicine to develop products involved in the prevention and control of coronary heart disease and metabolic syndromes. The company’s CLIA-certified laboratory in Irvine, California offers a comprehensive test menu including standard-of-care laboratory tests, molecular genetic test assays, DNA sequencing of inherited cardio-metabolic diseases, and novel risk assessment products.
Official Representative: Cynthia French, Chief Scientific Officer
Located in Sunnyvale, California, BioNex Solutions is revolutionizing laboratory automation in research and clinical laboratories by rethinking productivity, reliability, and flexibility. The company’s approach is to develop a strong relationship with each customer that continues long after the sale. The BioNex team of engineers and scientists have decades of experience in drug discovery, molecular biology and laboratory robotics, allowing them to fully comprehend and execute your automation goals.
Official Representative: Tony Lima, Chief Executive Officer
Located in Hercules, California, Bio-Rad has been at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad serves more than 100,000 research and industry customers worldwide through its global network of operations. The Company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011.
Official Representative: Brad Crutchfield, President, Life Sciences Group
Cynvenio Biosystems is a California biotech company dedicated to providing game-changing technology to improve the diagnosis and treatment of cancer patients. Cynvenio’s rare cell detection and mutational profiling applications include the LiquidBiopsy™ blood test for the early detection of cancer, and the selection of individual patient therapeutic solutions.
Official Representative: André de Fusco, Chief Executive Officer
Enzymatics Inc. is an independent, ISO certified OEM manufacturer of enzymes that brings to the marketplace a unique, quality oriented, and customer focused approach to protein production. The company was founded in 2006 to specifically address the needs of commercial entities engaged in the development, manufacture, and distribution of platforms dedicated to nucleic acid identification.
Official Representative: Jon DiVincenzo, President and CEO
Formulatrix, Inc. of Waltham, Massachusetts, is a 100 percent employee-owned private company that was established in 2002 to provide protein crystallization automation solutions. Since then, the company has begun developing the next generation of liquid handlers using microfluidic technology. The company supplies software and robotic automation solutions to leading pharmaceutical companies and academic research institutions around the world.
Official Representative: Jeremy Stevenson, President
Linkage Biosciences Inc., located in South San Francisco, California, produces molecular diagnostics products that dramatically improve and expedite complex genetic testing and with an initial focus on the solid organ and stem cell transplantation market.
Official Representative: Zachary Antovich, President and CEO
Located in Redwood City, California, Pathwork develops and commercializes innovative, high-value molecular diagnostics for oncology. The company’s products include a microarray-based gene expression test that aids in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers.
Official Representative: Lee McCracken, President and CEO
Founded in 2007, Quanterix is developing an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. The Single Molecule Array (Simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant commercial unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. Quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at Tufts University by Dr. David Walt, scientific founder of Quanterix and Illumina (NASDAQ: ILMN).
Official Representative: Paul Chapman, President and CEO
RainDance Technologies is pioneering digital biology and powering ground-breaking human health and life science research with its novel droplet-based technologies. The complete RainDance solution includes automated instrumentation, customizable bioinformatics and high-value consumables and reagents for applications including targeted next-generation DNA sequencing, methylation, digital PCR and single cell analysis.
Official Representative: Roopom Banerjee, President and CEO
Senova Systems develops, manufactures and sells next generation sensor systems based on coupling its patented chemistry with advanced materials, and proprietary microelectronics. Senova Systems’ first focus is a revolutionary pHit™ pH sensor platform, which replaces current glass electrodes with solid-state, smart sensors which contain no glass and require no user calibration. This breakthrough offers significant operational and economic benefits in the life science, food and beverage, dairy, petrochemical, water and environmental sectors, and will ultimately enable novel advances in healthcare and other specialized applications unachievable with conventional pH electrodes.
Official Representative: Lee Leonard, Chief Executive Officer
SFC Fluidics is a privately-held, early-stage company headquartered at the Arkansas Research and Technology Park in Fayetteville, Arkansas. Launched in 2003, SFC Fluidics' mission is to provide innovative microfluidic technologies that enable ever more powerful miniaturized analytical tools, laboratories-on-a-chip, clinical diagnostics, and life science research instruments. SFC's product lines span three categories: high performance components (microfluidic pumps, connectors, detector arrays, and nanopipettes); instrument subsystems (solvent delivery, cell injection, electrochemical detection, chip-based chromatography and on-chip separations); and complete diagnostic platforms (portable benchtop and handheld platforms for in vitro diagnostics).
Official Representative: Sai Kumar, Vice President, R&D
Siemens Healthcare Diagnostics offers a broad portfolio of performance-driven diagnostics solutions that provide more effective ways to assist in the diagnosis, monitoring and management of disease. Their products and services offer the right balance of science, technology and practicality across the healthcare continuum to provide healthcare professionals with the vital information they need to deliver better, more personalized healthcare to patients around the globe. Siemens molecular testing systems enable early detection of major infectious diseases; monitoring of treatment efficacy; and selection of targeted, individualized treatment options.
Official Representative: Trevor Hawkins, Senior Vice President, Strategy, Innovation and Business Development
TessArae® designs and commercializes targeted sequencing applications in the fields of human disease and industrial testing. Combining the sensitivity of PCR with the specificity of DNA sequence, the company’s products include complete platform solutions for carrier screening, oncogene testing, respiratory pathogen detection and microbial contamination.
Official Representative: L. Thomas Richards, President and CEO
Driven by a strong spirit of entrepreneurship and an innovative attitude, the founders of Trinean recognized that the move towards small-scale methods in the life sciences demands the development of versatile instruments able to rapidly analyze very small samples. This lead them to pioneer a new approach for measuring microliter samples based on their expertise in both spectrometry and microfluidics. Trinean focuses on micro-volume molecular spectroscopy that combines best in class analytical software with a highly standardized read-out platform.
Official Representative: Philippe Stas, Chief Executive Officer
"ALDA is the single most important organization that I belong to because it keeps me in touch with everyone that matters in our industry."